Muscoli, S.; Barillà , F.; Tajmir, R.; Meloni, M.; Della Morte, D.; Bellia, A.; Di Daniele, N.; Lauro, D.; Andreadi, A.
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics 2022, 14, 1730.
https://doi.org/10.3390/pharmaceutics14081730
AMA Style
Muscoli S, Barillà F, Tajmir R, Meloni M, Della Morte D, Bellia A, Di Daniele N, Lauro D, Andreadi A.
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics. 2022; 14(8):1730.
https://doi.org/10.3390/pharmaceutics14081730
Chicago/Turabian Style
Muscoli, Saverio, Francesco Barillà , Rojin Tajmir, Marco Meloni, David Della Morte, Alfonso Bellia, Nicola Di Daniele, Davide Lauro, and Aikaterini Andreadi.
2022. "The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective" Pharmaceutics 14, no. 8: 1730.
https://doi.org/10.3390/pharmaceutics14081730
APA Style
Muscoli, S., Barillà , F., Tajmir, R., Meloni, M., Della Morte, D., Bellia, A., Di Daniele, N., Lauro, D., & Andreadi, A.
(2022). The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics, 14(8), 1730.
https://doi.org/10.3390/pharmaceutics14081730
